CONGRATS TO OUR 2022 KL2 SCHOLAR AWARDEES

KL2 Scholars 2022

Nisha Fahey, DO
Department of Pediatrics, Population and Quantitative Health Sciences
Mentors: Jeroan Allison, MD, MS; Arvin Garg, MD, MPH
Project Title: Enabling Community-Based Kangaroo Care to Mitigate Health Inequities Among Preterm Infants

Lara Kovell, MD
Department of Medicine, Division of Cardiology
Mentor: David McManus, MD, ScM
Project Title: Development of a Mobile Health Intervention for Blood Pressure Management in Pregnancy

Laurel O’Connor, MD
Department of Emergency Medicine
Mentor: Edwin Boudreaux, MD
Project Title: A mobile-Integrated Health Intervention for the Management of Acute Myocardial Infarction and Chronic Obstructive Pulmonary Disease

Martha Zimmermann, PhD
Department of Psychiatry
Mentor: Nancy Aust, MD, MBA, MS, DFAPA, FACLP
Project Title: Developing a scalable Intervention to Prevent Perinatal Anxiety in Obstetric Settings

WHAT'S NEW?

01 News
03 Events
09 Funding
13 Education
2022 KL2 SCHOLAR AWARDEES
These four Scholars will pursue career development full-time for two years, receiving mentorship and completing projects designed to launch their independent research careers while developing the skills needed to compete for independent funding. For more details about this annually awarded training program CLICK HERE.

KL2 Scholars 2022

Nisha Fahey, DO
Department of Pediatrics, Population and Quantitative Health Sciences
Mentors: Jeroan Allison, MD, MS, Arvin Garg, MD, MPH
Project Title: Enabling Community-Based Kangaroo Care to Mitigate Health Inequities Among Preterm Infants

Lara Kovell, MD
Department of Medicine, Division of Cardiology
Mentor: David McManus, MD, ScM
Project Title: Development of a Mobile Health Intervention for Blood Pressure Management in Pregnancy

Laurel O’Connor, MD
Department of Emergency Medicine
Mentor: Edwin Boudreaux, MD
Project Title: A mobile Integrated Health Intervention for the Management of Acute-Phase Exacerbation of Congestive Health Failure and Chronic Obstructive Pulmonary Disease

Martha Zimmermann, PhD
Department of Psychiatry
Mentor: Nancy Byatt, DO, MBA, MS, DFAPA, FACLP
Project Title: Developing a Scalable Intervention to Prevent Perinatal Anxiety in Obstetric Settings
Rigor and Reproducibility Seminar

“Does Science Self-Correct?”

Given jointly by the University of Massachusetts Medical School, Population and Quantitative Health Sciences and UMASS Boston, Gerontology Department and Gerontology Institute

Monday, October 17, 2022
12:00 – 1:00 PM

Presented by: Ivan Oransky, M.D.
Editor-in-Chief, Spectrum Distinguished Writer in Residence, New York University’s Arthur Carter Journalism Institute Co-Founder, Retraction Watch Past President, Association of Health Care Journalists

Join from PC, Mac, Linux, iOS or Android:
https://umassmed.zoom.us/j/96838812715?
pwd=bEFwanZZG4xRi93a3BVZlVqUndlUT09
Password: 704923

Ivan Oransky, MD, is co-founder of Retraction Watch, editor in chief of Spectrum, and distinguished writer in residence at New York University’s Arthur Carter Journalism Institute. Ivan, a graduate of the NYU School of Medicine, previously was president of the Association of Health Care Journalists and vice president of editorial at Medscape. He has also held editorial leadership positions at MedPage Today, Reuters Health, Scientific American and The Scientist. He is the recipient of the 2015 John P. McGovern Medal for excellence in biomedical communication from the American Medical Writers Association, and in 2017 was awarded an honorary doctorate in civil laws from The University of the South (Sewanee). In 2019, the judges for the John Maddox Prize, which promotes those who stand up for science in the face of hostility, gave him a commendation for his work at Retraction Watch.
The NCATS Assay Guidance Manual (AGM) program is hosting a two-day workshop that will cover a broad range of critical concepts underlying assay development and implementation for high-throughput screening and lead discovery projects. This workshop is designed to disseminate critical information about the implementation of robust assay methods and is particularly relevant for researchers developing molecular probes or clinical candidates. Many of the instructors have 20 to 30 years of experience in the field of drug discovery and will share information not readily found in a classroom or published material outside of the AGM. The workshop also will cover emerging technologies and modalities in drug discovery, including the use of DNA-encoded libraries and 3-D tissue models in drug discovery.
The Nurses Special Interest Group, part of the UMCCTS, is hosting this webinar series and encourages nurse scientists, clinicians and individuals from all UMCCTS campuses and disciplines to attend.

This October 20th webinar, "Mind-Body Connection: Optimism & Stroke Recovery" will be presented by Dr. Yun-Ju Lai of UMass Lowell Solomont School of Nursing.

MIND-BODY CONNECTION: OPTIMISM AND STROKE RECOVERY
OCTOBER 20, 2022
12:00-1:00 PM | VIRTUAL

PASSWORD: 031335

Dr. Lai's research program focuses on dissecting mind-and-body connections, particularly in identifying serum biomarkers, i.e., cytokines and chemokines, to predict disease progression in stroke, cancer, and COVID-19. In this study, we found that optimism level is negatively associated with plasma interleukin-6 and C-reactive protein in ischemic stroke patients. Moreover, optimism might reduce stroke severity and enhance physical recovery in the stroke population. The long-term goal of my research is to develop a suitable intervention strategy to boost patients' optimism levels, which will accelerate physical recovery and reduce inflammation.
Rigor and Reproducibility Seminar

“Are Predatory Journals Bad Hombres?”

Given jointly by the University of Massachusetts Medical School, Population and Quantitative Health Sciences and UMASS Boston, Gerontology Department and Gerontology Institute

Monday, October 31, 2022
12:00 – 1:00 PM

Presented by: David Moher, PhD, MSc, BA
Senior Scientist, Clinical Epidemiology Program
Ottawa Hospital Research Institute

Join from PC, Mac, Linux, iOS or Android:
https://umassmed.zoom.us/j/93652990006?
pwd=ZU9GWEREajh5TUFsdFVPcGZicVB3dz09
Password: 882650

David Moher is a senior scientist, clinical epidemiology program, Ottawa Hospital Research Institute, where he directs the centre for journalology (i.e., publication science). Dr. Moher is also Professor, School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa. Dr. Moher holds an MSc in epidemiology and PhD in clinical epidemiology and biostatistics. Dr. Moher is a fellow of the Royal Society of Canada and a fellow of the Canadian Academy of Health Sciences.
**K CLUB**

Next Meeting - October 12th & October 26th, 2022
4:00-5:00 PM ~ Virtual, Zoom

K Club supports junior faculty in the development of K-level “Mentored Research Scientist Career Development Award” applications. According to NIH, the award is intended to provide either progressive training or further experience in research related to biomedical, behavioral, or clinical sciences. The mentored approach provides the knowledge required for the K-Awardee to progress into an independent researcher over the award period.

K Club meets bi-weekly on the 2nd and 4th Wednesdays of the month from 4-5 pm via Zoom. Attendance at K Club meetings can be for information purposes and/or for review of your application. The group meets to outline the K-Award writing process and to review material being submitted by/to the group for input. To register to attend K Club, please email Robyn.Leonard@umassmed.edu.

**R CLUB**

Next Meeting October 11th & 25th, 2022
11:00 AM -12:00 PM ~ Virtual, Zoom

Are you an early stage investigator looking to write your first R21 or R01? Would you like input and feedback on your proposal from experienced faculty who have been there before? The UMCCTS is pleased to offer the R Club, a peer group that meets twice a month to review and plan for successful R-level grant submissions. Interested? Please email Nathaniel.Hafer@umassmed.edu to be added to our mailing list.

Join from PC, Mac, Linux, iOS or Android: https://umassmed.zoom.us/j/5682209338?pwd=dHRmWnBnWHBZZ1I0c3B4M05Pc3BTdz09
Password: 809084.
DO YOU HAVE GROUNDBREAKING TECHNOLOGY THAT CAN DIAGNOSIS OR TREAT DISORDERS OF NERVOUS SYSTEM?

Two incubator hubs, CIMIT’s CINTA and NeuroTech Harbor, through the NIH Blueprint MedTech program, are currently seeking proposals from academic and industry applicants who have emerging technologies that aim to improve the diagnosis and/or treatment of nervous system disorders.

A major emphasis of this program is to create opportunities for diverse innovators, including those who have been traditionally underrepresented in the neurotech space.

Program Details:

- Awards up to $500K to help support development toward commercialization.
- Mentorship from experienced commercialization experts
- Support to address business, regulatory, clinical, and technical project aspects

Pre-proposals are due no later than October 24th.

Learn More or Apply Have questions about the program?

Visit our FAQs or Register for an Informational Webinar
THE NATIONAL INSTITUTES OF HEALTH (NIH) IS PROUD TO ANNOUNCE THE RADx® TECH FOR MATERNAL HEALTH CHALLENGE.

The competition will award up to $8 million in prizes to teams or businesses that develop medtech solutions to improve postpartum health outcomes in areas where access to maternal care services is limited.

Apply by 11/11/22

MORE INFO HERE
JOIN THE CHALLENGE TO DEVELOP, TRAIN, AND TEST MODELS TO AID IN PREDICTING THE SUSCEPTIBILITY TO AND LIKELIHOOD OF DEVELOPING PASC/LONG COVID IN PATIENTS WITH SARS-COV-2 INFECTION.

Long COVID, can affect anyone, including children, and it can develop in people who had asymptomatic, mild, or severe COVID-19. To complement the National Institutes of Health (NIH) other Long COVID research initiatives, like Researching COVID to Enhance Recovery (RECOVER), the RADx-Radical (RADx-rad) program at the NIH is launching the Long COVID Computational Challenge (L3C). NIH designed this challenge to support creative data-driven solutions that meaningfully advance the current understanding of the risks of developing PASC/Long COVID. The total prize for this Challenge will be up to $500,000.

Submissions Due: December 15
FUNDING

PAR-22-105, PAR-22-109 AND PAR-22-106: DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH
(R01 Clinical Trial Optional)
(R21 Clinical Trial Optional)
(R03 Clinical Trial Not Allowed)

Closing dates for applications: October 2022 with ongoing cycles through February 2025
LOIs due 30 days prior (Required for R01 & R21)

These FOAs support studies to identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, broadly defined. Studies that focus on underrepresented communities or that advance dissemination and implementation research methods and measures are encouraged.

More Info (R01)
More info (R21)
More info (R03)

CLINICAL TRIAL READINESS FOR RARE DISEASES, DISORDERS, AND SYNDROMES
(R21 CLINICAL TRIAL NOT ALLOWED)
(R03 CLINICAL TRIAL NOT ALLOWED)

CLOSING DATES FOR APPLICATIONS:
OCTOBER 17, 2022 WITH ONGOING CYCLES THROUGH OCTOBER 17, 2024

These FOAs support clinical projects addressing critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that enable efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, develop and test rigorous biomarkers and clinical outcome assessment measures, and/or define the presentation and course of a rare disease.

More info (R21)
More Info (R03)
RFA-AI-22-055:
Maintaining Immunity After Immunization
(U01 Clinical Trial Not Allowed)
Closing date for applications: January 13, 2023
This FOA promotes research to improve understanding of how vaccines against infectious agents lead to durable protective immunity. This initiative will support studies that define components and mechanisms of the immune system that determine such durability. Applications must propose use of human cells/tissues to decipher the human response elicited through vaccination, though animal studies may also be included.

RFA-EB-22-002:
HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices
(R18 Clinical Trial Not Allowed)
Closing date for applications: June 17, 2025
This opportunity targets development of clinical-grade prototypes intended for use as safe, effective, and non-addictive device-based technologies and approaches to treat pain. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies.

NOT-OD-22-216 and NOT-OD-22-217:
Notices of Intent to Publish a Funding Opportunity Announcement for Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research
(R24, R01)
Estimated FOA Publication Date: November 4, 2022
First Estimated Application Due Date: January 6, 2023

Links for More Info:
EDUCATION

ARE YOU AN EARLY-CAREER HEALTH RESEARCHER WORKING ON A BIG GRANT IN THE NEXT FEW MONTHS (BUT YOU FEEL LIKE YOU HAVEN’T GOT A CLUE)?

Learn how to write a clearer, more persuasive grant application when you sign up for this FREE...

Grant Writing Fundamentals Workshop with Sarah Dobson, Research Grant Consultant - Brought to you by Edge for Scholars

Next session begins October 17, 2022 - SAVE A SEAT HERE

This 12-week online training program will demystify the grant writing process and show you how to write your most competitive research proposal—ever.

Learn the strategic moves that will help you transform your research grant into a powerful competitor, with six video tutorials and weekly guidance delivered straight to your inbox.

Every other week, you’ll be invited to attend a live Q&A call where you can get your grant-writing questions answered by Sarah Dobson, a research grant consultant who’s helped PIs bring in more than $40 Million in research funding in fiercely competitive environments like NIH and CIHR.

CITE & SUBMIT

Please cite the NIH CTSA award any time you use The UMMS Center for Clinical and Translational Science resources, services and facilities or received funding through the Center. “The project described is supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1 TR001453, (or TL1 TR001454, or KL2 TR001455, as appropriate). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.”
SHARE YOUR SUCCESS STORY!
Have you had your research published that cites the UMass Center for Clinical and Translational Science? Has your patent been filed on technology developed using Center funding or resources? Did your pilot project receive external grant funding? Share it with us at ccts@umassmed.edu. Sharing your success demonstrates the importance and effect of the Center for Clinical and Translational Science at UMass.

NEWSLETTER SUBMISSIONS
To be included in the CCTS Monthly Newsletter, please send announcements, including a link, to ccts@umassmed.edu. The newsletter is published the first week of each month.

KATHERINE LUZURIAGA, MD
PI AND DIRECTOR, UMCCTS

TERENCE R. FLOTTE, MD
CO-DIRECTOR, UMCCTS